Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
22.13 -0.14 -0.63%
Live - 5344 symbols - heartbeat 226s ago · 2026-10-08 07:56
Pre-market 21.97 -0.74%
After-hours 22.52 +1.76%
Overnight 22.09 -0.18%
Market cap
2.65B
P/B
4.19
EPS
-1.72
Reader sentiment Are you bullish or bearish on NAMS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51
    Market Newswire · 2026/6/30
  • Rating change
    A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58
    Market Newswire · 2026/8/6
  • Rating change
    Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/3/19
  • Rating change
    Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/5/8
  • Rating change
    A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $45 to $48
    Market Newswire · 2026/5/8
  • Rating change
    H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
    TipRanks · 2026/5/8
  • Rating change
    Truist Financial Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
    Market Newswire · 2026/3/19
  • Rating change
    RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $47
    Market Newswire · 2026/5/6
  • Rating change
    TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
    Market Newswire · 2026/2/21
  • BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/9/22
  • Rating change
    William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
    Market Newswire · 2026/9/18
  • Rating change
    Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/8/4
  • Rating change
    Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/9/8
  • Rating change
    Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/8/8
  • H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52
    Market Newswire · 2026/9/30
  • RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $42
    Market Newswire · 2026/10/5
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
    Market Newswire · 2026/9/22
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
    Market Newswire · 2026/9/8
  • Rating change
    A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52
    Market Newswire · 2026/8/7
  • Rating change
    BMO Capital Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $58
    Market Newswire · 2026/7/21

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:56:10 · For reference only, not investment advice and not tailored to your situation.